TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.
News  ›  Benzinga

CORRECTION – Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation

Benzinga Logo Benzinga • •By Globe Newswire
CORRECTION – Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation

Inspira Technologies Oxy (NASDAQ: IINN) announced a non-binding term sheet for acquiring an advanced liquid biopsy diagnostics business and receiving a $15 million strategic equity investment at a $180 million pre-money valuation. The acquisition includes an AI-powered platform for isolating and characterizing circulating tumor cells from blood samples, with initial focus on breast cancer. The company plans to pursue FDA 510(k) clearance and has structured the deal to protect existing shareholders' economic interests in its respiratory and blood monitoring technologies through contingent value rights.

Insights
IINN   positive

The company is expanding into a high-growth liquid biopsy market ($58 billion projected over a decade) with a $15 million strategic investment at a significant premium to current market cap. The acquisition provides a development-ready platform with clear FDA regulatory pathway and existing reimbursement codes, while the shareholder protection framework preserves value from existing technologies. These factors represent substantial growth opportunities and strategic validation.

Keywords
#liquid biopsy #cancer diagnostics #acquisition #equity investment #FDA clearance #circulating tumor cells #medical device #strategic investment

Tickers
IINN IINNW
← Prev: Oracle: A Hard Pass—or a Hard-to-Pass Opportunity?